NCT00118950View on ClinicalTrials.gov

Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2001

Study Completion Date

March 31, 2003

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Metformin

Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.

DRUG

Repaglinide

Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.

DRUG

Placebo-Metformin.

Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.

DRUG

Placebo-Repaglinide.

Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.

OTHER

Diet-only.

Diet-only treatment. Duration: One month.

Trial Locations (1)

2820

Steno Diabetes Center, Gentofte Municipality

All Listed Sponsors
lead

Steno Diabetes Center Copenhagen

OTHER

NCT00118950 - Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet | Biotech Hunter | Biotech Hunter